A Phase III, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine (Fluvirin) in Healthy Adults

Trial Profile

A Phase III, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine (Fluvirin) in Healthy Adults

Completed
Phase of Trial: Phase III

Latest Information Update: 07 May 2014

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Aug 2013 Planned end date changed from 31 Aug 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 19 Jun 2013 New source identified and integrated (ClinicalTrials.gov; NCT01885117).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top